Clinical benefit of trabectedin in uterine adenosarcoma

Brett A. Schroeder, Eve Rodler, Elizabeth T. Loggers, Seth M. Pollack, Robin L. Jones

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Uterine adenosarcoma is an extremely rare uterine malignancy, and the utility of chemotherapy in this disease is not well defined. This study assessed the safety and efficacy of trabectedin in patients with recurrent/metastatic uterine adenosarcoma with sarcomatous overgrowth. A retrospective search of a prospectively maintained database was performed to identify patients with adenosarcoma treated with trabectedin between 2010 and 2012, within a compassionate use trial. Three patients with recurrent/metastatic uterine adenosarcoma treated with trabectedin were identified. All three patients tolerated the drug well. Two patients obtained prolonged clinical benefit from treatment, one having received 17 cycles and another 11 cycles of therapy. Trabectedin is well tolerated and has clinical activity in recurrent/metastatic uterine adenosarcoma.

Original languageEnglish (US)
Article number501
JournalMedical Oncology
Volume30
Issue number2
DOIs
StatePublished - Jun 2013
Externally publishedYes

Fingerprint

trabectedin
Adenosarcoma
Compassionate Use Trials
Adenosarcoma of the uterus
Databases
Safety
Drug Therapy

Keywords

  • Clinical benefit
  • Systemic therapy
  • Trabectedin
  • Uterine adenosarcoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Hematology
  • Medicine(all)

Cite this

Schroeder, B. A., Rodler, E., Loggers, E. T., Pollack, S. M., & Jones, R. L. (2013). Clinical benefit of trabectedin in uterine adenosarcoma. Medical Oncology, 30(2), [501]. https://doi.org/10.1007/s12032-013-0501-3

Clinical benefit of trabectedin in uterine adenosarcoma. / Schroeder, Brett A.; Rodler, Eve; Loggers, Elizabeth T.; Pollack, Seth M.; Jones, Robin L.

In: Medical Oncology, Vol. 30, No. 2, 501, 06.2013.

Research output: Contribution to journalArticle

Schroeder, BA, Rodler, E, Loggers, ET, Pollack, SM & Jones, RL 2013, 'Clinical benefit of trabectedin in uterine adenosarcoma', Medical Oncology, vol. 30, no. 2, 501. https://doi.org/10.1007/s12032-013-0501-3
Schroeder, Brett A. ; Rodler, Eve ; Loggers, Elizabeth T. ; Pollack, Seth M. ; Jones, Robin L. / Clinical benefit of trabectedin in uterine adenosarcoma. In: Medical Oncology. 2013 ; Vol. 30, No. 2.
@article{ea5ac89012e44b42b26e2f7f0d917a13,
title = "Clinical benefit of trabectedin in uterine adenosarcoma",
abstract = "Uterine adenosarcoma is an extremely rare uterine malignancy, and the utility of chemotherapy in this disease is not well defined. This study assessed the safety and efficacy of trabectedin in patients with recurrent/metastatic uterine adenosarcoma with sarcomatous overgrowth. A retrospective search of a prospectively maintained database was performed to identify patients with adenosarcoma treated with trabectedin between 2010 and 2012, within a compassionate use trial. Three patients with recurrent/metastatic uterine adenosarcoma treated with trabectedin were identified. All three patients tolerated the drug well. Two patients obtained prolonged clinical benefit from treatment, one having received 17 cycles and another 11 cycles of therapy. Trabectedin is well tolerated and has clinical activity in recurrent/metastatic uterine adenosarcoma.",
keywords = "Clinical benefit, Systemic therapy, Trabectedin, Uterine adenosarcoma",
author = "Schroeder, {Brett A.} and Eve Rodler and Loggers, {Elizabeth T.} and Pollack, {Seth M.} and Jones, {Robin L.}",
year = "2013",
month = "6",
doi = "10.1007/s12032-013-0501-3",
language = "English (US)",
volume = "30",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press",
number = "2",

}

TY - JOUR

T1 - Clinical benefit of trabectedin in uterine adenosarcoma

AU - Schroeder, Brett A.

AU - Rodler, Eve

AU - Loggers, Elizabeth T.

AU - Pollack, Seth M.

AU - Jones, Robin L.

PY - 2013/6

Y1 - 2013/6

N2 - Uterine adenosarcoma is an extremely rare uterine malignancy, and the utility of chemotherapy in this disease is not well defined. This study assessed the safety and efficacy of trabectedin in patients with recurrent/metastatic uterine adenosarcoma with sarcomatous overgrowth. A retrospective search of a prospectively maintained database was performed to identify patients with adenosarcoma treated with trabectedin between 2010 and 2012, within a compassionate use trial. Three patients with recurrent/metastatic uterine adenosarcoma treated with trabectedin were identified. All three patients tolerated the drug well. Two patients obtained prolonged clinical benefit from treatment, one having received 17 cycles and another 11 cycles of therapy. Trabectedin is well tolerated and has clinical activity in recurrent/metastatic uterine adenosarcoma.

AB - Uterine adenosarcoma is an extremely rare uterine malignancy, and the utility of chemotherapy in this disease is not well defined. This study assessed the safety and efficacy of trabectedin in patients with recurrent/metastatic uterine adenosarcoma with sarcomatous overgrowth. A retrospective search of a prospectively maintained database was performed to identify patients with adenosarcoma treated with trabectedin between 2010 and 2012, within a compassionate use trial. Three patients with recurrent/metastatic uterine adenosarcoma treated with trabectedin were identified. All three patients tolerated the drug well. Two patients obtained prolonged clinical benefit from treatment, one having received 17 cycles and another 11 cycles of therapy. Trabectedin is well tolerated and has clinical activity in recurrent/metastatic uterine adenosarcoma.

KW - Clinical benefit

KW - Systemic therapy

KW - Trabectedin

KW - Uterine adenosarcoma

UR - http://www.scopus.com/inward/record.url?scp=84874345950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874345950&partnerID=8YFLogxK

U2 - 10.1007/s12032-013-0501-3

DO - 10.1007/s12032-013-0501-3

M3 - Article

C2 - 23456619

AN - SCOPUS:84874345950

VL - 30

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 2

M1 - 501

ER -